7 IT)S 8/07/03 Atty. Dkt. No. 040679-1159

AU6 2 1 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicant:

Hisatomo OHKI et al.

Title:

INHALANT MEDICATOR

Appl. No.:

09/703,794

Filing Date:

11/02/2000

Examiner:

Unassigned

Art Unit:

3761

RECEIVED

AUG 2 5 2003

TECHNOLOGY CENTER REPORT

UNDER 37 CFR § 1.56

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), after the mailing date of the first Office Action on the merits, and within three months of the mailing date of the foreign search report. A statement is provided.

RELEVANCE OF EACH DOCUMENT

The foregoing documents came to Applicants' attention during a search of the corresponding European application. A copy of the European Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 C.F.R. §1.97(e)(1) that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully subported,

Pavan K. Agarwal

Attorney for Applicant

Registration No. 40,888

Date <u>August 21, 2003</u>

FOLEY & LARDNER Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5143 Telephone: (202) 945-6162

Facsimile:

(202) 672-5399